ORGS

Insider Trades

Name	Value	Action	Price	Current Price
Safier Jacob10 Percent Owner $5.8k10k shares SellJun 24, 2024 $0.5814 --
Safier Jacob10 Percent Owner $5.8k10k shares BuyJun 24, 2024 $0.58 --

News

newsfilecorp.comOkogen Acquires Ranpirnase Assets and Intellectual Property Portfolionewsfilecorp.comMar 26

Trade ORGS

About Orgenesis Inc.

Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.

CEO: Vered Caplan
IPO Date: Mar 13, 2012

Market Data

Open: $0.3184
High: $0.3184
Low: $0.3184
Volume: 100
Avg Volume: 1.9K
52W High: $5.89
52W Low: $0.02

Valuation

Market Cap: $1.6M
Enterprise Value: $23M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-17M
Revenue: $530k
Net Income: $-55M
Cash: $837k
Debt: $23M

Events

EarningsAug 7

EPS est. -2.3